Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02715570
Other study ID # PC_ASP_001
Secondary ID 2015-003327-64
Status Completed
Phase Phase 1
First received
Last updated
Start date October 23, 2017
Est. completion date April 27, 2018

Study information

Verified date April 2018
Source Pulmocide Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date April 27, 2018
Est. primary completion date April 27, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

All subjects (Cohorts 1, 2 & 3)

- Male or female, aged between 18 and 65 years inclusive (at the time of consent) who fit one of the following criteria: Women of childbearing potential who are willing and able to use required contraception from screening until 30 days after receipt of the final dose; Women of non-childbearing potential defined as being amenorrhoeic or have been permanently sterilised; Men who are willing and able to use required contraception from the time of the first dose, until 90 days after receipt of the final dose of study medication.

- Females with a negative pregnancy test at screening and at Day -1.

- Willing and able to adhere to the restrictions and prohibitions required by this protocol.

- Signed informed consent form.

- Body weight = 50 kg and body mass index (BMI) within the range 18 — 30 kg/m2 (inclusive).

- Average QTcF <450 msec at screening and pre-dose.

- Vital signs assessments within normal ranges

Healthy Subjects (Cohorts 1 and 2)

- Healthy as determined by a physician based on a full medical examination.

- Spirometry readings (FEV1 and FVC) to be = 80% of predicted value and FEV1/FVC ratio > 0.7 at screening.

Subjects with Asthma (Cohort 3)

- Diagnosis of asthma.

- Positive result to methacholine challenge at the screening visit.

- FEV1 >60% of predicted normal value at screening.

- Stable asthma based on physician assessment at screening, with no changes of therapy in the 12 weeks prior to screening and no hospitalization or visit to accident and emergency for asthma in the 12 months prior to screening

- Otherwise healthy on the basis of a full medical examination at screening

Exclusion Criteria:

All subjects (Cohorts 1, 2 & 3)

- Any acute illness.

- Upper or lower respiratory tract infection within 4 weeks of the screening visit or randomisation.

- Use of prescription medications within 14 days of the Screening visit.

- Taking over the counter (OTC) medications other than vitamins or multivitamins, within 14 days prior to Screening.

- History of regular alcohol consumption within 6 months of the study with average weekly intake of >21 units for males, or >14 units for females.

- History of drug or alcohol abuse within the previous 5 years.

- Smoker (regular or irregular), or has smoked or used nicotine-containing products (including e-cigarettes) within the 6 months prior to screening or has a smoking history of = 10 pack years.

- Positive test for HIV-1 & -2 antibodies at screening.

- Positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result at screening.

- Positive test for alcohol, smoking or drugs of abuse at screening or Day -1.

- Received an experimental drug or used an experimental medical device within last 3 months.

- Allergy to any of the active or inactive ingredients in the study medication.

- Donation of blood in excess of 500 mL within a 3 month period prior to dosing, or if study participation would result in blood loss in excess of 500 mL in a 3 month period.

- Mentally or legally incapacitated.

- An employee of the Sponsor or contract research organisation (CRO), or a relative of an employee of the Sponsor or CRO.

- Unable or unwilling to undergo multiple venepuncture procedures or poor access to veins suitable for cannulation.

- Pregnant or lactating female

Healthy subjects (Cohorts 1 and 2)

- Any chronic illness or clinically relevant abnormality identified on the screening medical assessment, laboratory tests or ECG.

Subjects with asthma (Cohort 3)

- Had an episode of life-threatening asthma.

- Presence of clinically significant diseases other than asthma, hyper-responsive airways, seasonal allergic rhinitis or atopic diseases.

- Experienced an acute asthma exacerbation in the 12 months prior to screening requiring hospitalisation or accident and emergency treatment or management with systemic or injectable steroids.

- Uncontrolled, or moderate to severe asthma based on PI assessment and/or use of prohibited medications, or has required treatment with these therapies in the previous 12 weeks.

- History or presence of any known conditions contraindicated for methacholine challenge.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PC945 - single doses
Safety and tolerability of single doses
Placebo - single doses
Safety and tolerability of single doses
PC945 - repeat doses
Safety and tolerability of repeat doses
Placebo - repeat doses
Safety and tolerability of repeat doses

Locations

Country Name City State
United Kingdom Parexel EPCU Harrow Middlesex

Sponsors (1)

Lead Sponsor Collaborator
Pulmocide Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Determination of exogenous fungal flora Assessment of fungal flora found in mouth and throat after dosing Cohort 1 (4 treatment periods) & Cohort 3 (1 treatment period) Day1 = 1 sample; Day3 = 1 sample. Cohort 2, Day 1 = 1 sample; Day 9 = 1 sample
Primary Incidence of treatment emergent adverse events Assessment of number of adverse events reported by subjects following dosing Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
Primary 12-lead ECG assessment Change from pre-dose values Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
Primary Vital signs assessment (blood pressure and heart rate - measured together) Change for pre-dose values Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
Primary Clinical laboratory assessments (blood and urine samples - measured together) Change from pre-dose values Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
Primary Spirometry assessment (FEV1 & FVC - measured together) Change from pre-dose values Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
Secondary Plasma concentration data of PC945 Blood levels of PC945 measured after dosing Cohort 1 (4 treatment periods) & Cohort 3 (1 treatment period) Day1 = 8 samples; Day2 = 2 samples; Day3 = 1 sample; F/U = 1 sample. Cohort 2 - Days1&7 = 10 samples; Days2,5,6 = 1 sample; Day8 = 2 samples; Day9 = 1 sample; F/U = 1 sample
Secondary Spirometry assessment (FEV1) Observed drops in FEV1 assessment after dosing patients with mild asthma Cohort 3 only - Day 1, 8 hours
See also
  Status Clinical Trial Phase
Suspended NCT01887457 - Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy Phase 2
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Enrolling by invitation NCT01617759 - Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
Terminated NCT03905447 - The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. Phase 2
Recruiting NCT04744454 - Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Completed NCT04935463 - Mucormycosis in COVID-19
Withdrawn NCT01188759 - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Phase 3
Completed NCT00473252 - Surveillance of Fungal Infections During Construction Activity N/A
Completed NCT00037206 - A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Phase 2/Phase 3
Completed NCT04818853 - COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Recruiting NCT06135597 - Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
Terminated NCT02646800 - Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Phase 4
Completed NCT00854607 - An Observational Study of Fungal Biomarkers (MK-0000-089) N/A
Completed NCT00388167 - Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Phase 4
Completed NCT05065658 - Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Completed NCT00005912 - Voriconazole to Prevent Systemic Fungal Infections in Children Phase 1
Completed NCT04431804 - THYME AND CARVACROLL Nanoparticle Effect on Fungi